RGDV-modified heptacyclic aldehyde, synthesis, antithrombotic activity and application thereof
The invention discloses Arg-Gly-Asp-Val modified heptacyclic aldehyde shown as the following formula in the specification, namely (2'S, 5'S)-tetrahydropyrazine[1', 2': 1, 6]bis{(1R)-[1-ethyl-Arg-Gly-Asp-Val]-2, 3, 4, 9-tetrahydro-1H-pyridine[3, 4-b]diindyl}-1', 4'-diket...
Gespeichert in:
Hauptverfasser: | , , , , |
---|---|
Format: | Patent |
Sprache: | chi ; eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The invention discloses Arg-Gly-Asp-Val modified heptacyclic aldehyde shown as the following formula in the specification, namely (2'S, 5'S)-tetrahydropyrazine[1', 2': 1, 6]bis{(1R)-[1-ethyl-Arg-Gly-Asp-Val]-2, 3, 4, 9-tetrahydro-1H-pyridine[3, 4-b]diindyl}-1', 4'-diketone, a preparation method thereof and anti-venous thrombosis activity thereof. Therefore, the invention discloses application of the Arg-Gly-Asp-Val modified heptacyclic aldehyde in preparation of anti-venous thrombosis drugs.
本发明公开了下式的Arg-Gly-Asp-Val修饰的七环醛,即(2'S,5'S)-四氢吡嗪[1',2':1,6]并双{(1R)-[1-乙基-Arg-Gly-Asp-Val]-2,3,4,9-四氢-1H-吡啶[3,4-b]并吲哚}-1',4'-二酮,公开了它的制备方法,公开了它的抗静脉血栓活性,因而本发明公开了它在制备抗静脉血栓药物中的应用。 |
---|